Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Primary antibodies

Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767) (MB613013)

Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767)
Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767)
Price(USD):
Spec:
  • 20ug
  • 50ug
  • 100ug
  • 1mg
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

  • SDS

Overview
Catalog No.MB613013
Description
Anti-Mouse CD223/LAG3 Nanobody (SAA0767) [SAA0767] (MB613013) is a alpaca monoclonal antibody detecting CD223 in ELISA, FCM. Suitable for Mouse.
Highlights
  • Flow Cytometry — Validated for flow cytometry applications.
Species reactivityMouse
ApplicationsELISA, FCM
Host speciesAlpaca
ClonalityMonoclonal
IsotypeVHH-8His-Cys-tag
Clone IDSAA0767
Target CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3
Endotoxin level < 10 EU/mg
Purity >95% as determined by SDS-PAGE.
Purification Purified by Nickel column.
Accession Q61790
Form Liquid
Storage buffer 0.01M PBS pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information
Application Dilution
ELISA 1:2000-1:20000
Stability and Storage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Background

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~56 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Workman, CJ. et al. (2002) European journal of immunology 32, 2255-63. PMID: 12209638
2. Workman, CJ. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 169, 5392-5. PMID: 12421911
3. Workman, CJ. et al. (2003) European journal of immunology 33, 970-9. PMID: 12672063
4. Workman, CJ. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 172, 5450-5. PMID: 15100286
5. Workman, CJ. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 174, 688-95. PMID: 15634887
6. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966
7. Maruhashi, T. et al. (2022) Immunity 55, 912-924.e8. PMID: 35413245
8. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082
9. Silberstein, JL. et al. (2024) Proceedings of the National Academy of Sciences of the United States of America 121, e2310866121. PMID: 38483996
10. Ming, Q. et al. (2024) Nature communications 15, 7513. PMID: 39209860
Note For research use only.
Images
  • Anti-Mouse LAG-3 Recombinant Nanobody (SAA0767)

    SDS-PAGE

    SDS-PAGE for Anti-Mouse CD223/LAG3 Nanobody (SAA0767)

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: [email protected]

Distributor list